Indian pharmaceutical company Strides Arcolab has entered
into a licensing agreement with US-based Gilead Sciences to manufacture and
distribute latter's low-cost HIV drug, Tenofovir Alafenamide (TAF), in
In a BSE filing, Strides Arcolab said, "It has entered into a licensing agreement with Gilead Sciences, Inc under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs."
Strides said that the license being granted to it extends to 112 countries.
TAF is an investigational product in the US and have not yet been determined safe and efficacious in humans.